Although tyrosine kinase inhibitors (gefitinib and erlotinib) can significantly prolong the survival of advanced NSCLC patients with EGFR‐sensitive mutations, acquired resistance inevitably develops because the underlying molecular mechanisms of NSCLC progression are still not fully understood.12, 13, 14. Here, EGFR is linked to non-small cell lung carcinoma.